Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway
- PMID: 29366704
- DOI: 10.1016/j.vaccine.2018.01.038
Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway
Abstract
Background: Adoption of varicella immunization in Europe is limited due to a predicted increase in the incidence of herpes zoster (HZ) resulting from a removal of exogenous boosting by varicella vaccination. Most available assessments of immunization strategies only considered universal varicella vaccination (alone or in combination with HZ by the live vaccine). The development of a new subunit recombinant zoster vaccine may provide new perspectives of HZ control.
Methods: We used a mathematical model for VZV in Norway based on the progressive immunity formulation of exogenous boosting. We evaluated a complete range of alternative immunization options against varicella and HZ including both universal and targeted varicella vaccination, either alone or with zoster immunization, and zoster immunization alone. We considered all values of the boosting intensity consistent with the Norwegian HZ incidence and compared the performance of the currently available live vaccine vs. a new recombinant vaccine.
Results: Universal varicella vaccination alone resulted in a marked increase in the incidence of HZ under all scenarios considered. Even under the most favorable hypotheses on the magnitude of the boosting intensity, this increase could be mitigated only by a parallel HZ immunization with a recombinant vaccine, assuming a long duration of protection. Targeted varicella immunization of adolescents resulted in a modest increase in the HZ incidence which could be counterbalanced by both the live and, especially, the recombinant vaccine.
Conclusions: Given current knowledge on HZ pathogenesis and exogenous boosting, targeted varicella vaccination of adolescents was the only strategy that was not predicted to impact the epidemiology of HZ, and therefore it may represent a suitable alternative to universal vaccination. These results are aimed to support vaccine policy decisions in Norway and other countries with a similar VZV epidemiology.
Keywords: Exogenous boosting hypothesis; Herpes zoster immunization; Mathematical models; Universal vs targeted varicella vaccination; Varicella-zoster virus (VZV).
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.Expert Rev Vaccines. 2025 Dec;24(1):556-569. doi: 10.1080/14760584.2025.2514527. Epub 2025 Jun 19. Expert Rev Vaccines. 2025. PMID: 40511469 Review.
-
The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.Am J Epidemiol. 2016 Apr 15;183(8):765-73. doi: 10.1093/aje/kwv240. Epub 2016 Mar 18. Am J Epidemiol. 2016. PMID: 26994062 Free PMC article.
-
Current and future effects of varicella and herpes zoster vaccination in Germany - Insights from a mathematical model in a country with universal varicella vaccination.Hum Vaccin Immunother. 2016 Jul 2;12(7):1766-76. doi: 10.1080/21645515.2015.1135279. Epub 2016 Feb 2. Hum Vaccin Immunother. 2016. PMID: 26835890 Free PMC article.
-
Point-Counterpoint: The Hope-Simpson Hypothesis and Its Implications Regarding an Effect of Routine Varicella Vaccination on Herpes Zoster Incidence.J Infect Dis. 2018 Sep 22;218(suppl_2):S57-S62. doi: 10.1093/infdis/jiy418. J Infect Dis. 2018. PMID: 30247602
-
Understanding the role of exogenous boosting in modeling varicella vaccination.Expert Rev Vaccines. 2018 Nov;17(11):1021-1035. doi: 10.1080/14760584.2018.1538801. Epub 2018 Nov 5. Expert Rev Vaccines. 2018. PMID: 30354696 Review.
Cited by
-
Clinical and economic impact of universal varicella vaccination in Norway: A modeling study.PLoS One. 2021 Jul 8;16(7):e0254080. doi: 10.1371/journal.pone.0254080. eCollection 2021. PLoS One. 2021. PMID: 34237090 Free PMC article.
-
The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study.BMC Med. 2018 Jul 17;16(1):117. doi: 10.1186/s12916-018-1094-7. BMC Med. 2018. PMID: 30012132 Free PMC article.
-
Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.PLoS One. 2021 May 13;16(5):e0251644. doi: 10.1371/journal.pone.0251644. eCollection 2021. PLoS One. 2021. PMID: 33984060 Free PMC article.
-
Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study.Med Biol Eng Comput. 2019 May;57(5):1121-1132. doi: 10.1007/s11517-018-1938-5. Epub 2019 Jan 16. Med Biol Eng Comput. 2019. PMID: 30652233
-
Varicella zoster virus vaccines: an update.Immunotargets Ther. 2019 Aug 6;8:15-28. doi: 10.2147/ITT.S176383. eCollection 2019. Immunotargets Ther. 2019. PMID: 31497569 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical